A user shared clinical trial data from 2007 indicating that ACE-031 increased muscle mass in preclinical mouse models, even when offset by glucocorticoid-induced muscle loss. The report notes that ACE-031 (an ActRIIB-based protein) demonstrated a 19% increase in lean body mass in mice and was being developed to treat muscular dystrophy and cancer-related atrophy.